Suscribirse

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure - 19/08/11

Doi : 10.1016/j.amjmed.2010.08.017 
Catherine Y. Wong, BS a, Sarwat I. Chaudhry, MD b, Mayur M. Desai, PhD, MPH c, Harlan M. Krumholz, MD, SM d, e, f, g,
a Weill Cornell Medical College, New York, NY 
b Section of General Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 
c Division of Chronic Disease Epidemiology, School of Public Health, Yale University School of Medicine, New Haven, Conn 
d Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 
e Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 
f Division of Health Policy and Administration, School of Public Health, Yale University School of Medicine, New Haven, Conn 
g Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Conn 

Requests for reprints should be addressed to Harlan M. Krumholz, MD, SM, Section of Cardiovascular Medicine, Yale University School of Medicine, 1 Church Street, Suite 200, New Haven, CT 06510

Abstract

Background

Comorbidity, disability, and polypharmacy commonly complicate the care of patients with heart failure. These factors can change biological response to therapy, reduce patient ability to adhere to recommendations, and alter patient preference for treatment and outcome. Yet, a comprehensive understanding of the complexity of patients with heart failure is lacking. Our objective was to assess trends in demographics, comorbidity, physical function, and medication use in a nationally representative, community-based heart failure population.

Methods

Using data from the National Health and Nutrition Examination Survey, we analyzed trends across 3 survey periods (1988-1994, 1999-2002, 2003-2008).

Results

We identified 1395 participants with self-reported heart failure (n=581 in 1988-1994, n=280 in 1999-2002, n=534 in 2003-2008). The proportion of patients with heart failure who were ≥80 years old increased from 13.3% in 1988-1994 to 22.4% in 2003-2008 (P <.01). The proportion of patients with heart failure who had 5 or more comorbid chronic conditions increased from 42.1% to 58.0% (P <.01). The mean number of prescription medications increased from 4.1 to 6.4 prescriptions (P <.01). The prevalence of disability did not increase but was substantial across all years.

Conclusion

The phenotype of patients with heart failure changed substantially over the last 2 decades. Most notably, more recent patients have a higher percentage of very old individuals, and the number of comorbidities and medications increased markedly. Functional disability is prevalent, although it has not changed. These changes suggest a need for new research and practice strategies that accommodate the increasing complexity of this population.

El texto completo de este artículo está disponible en PDF.

Keywords : Comorbidity, Disability, Epidemiology, Heart failure, Polypharmacy


Esquema


 Funding: Catherine Wong is a research fellow supported by Sarnoff Cardiovascular Research Foundation. Dr. Chaudhry is supported by a K23/Beeson Career Development Award from the National Institute on Aging and the American Federation for Aging Research. Dr. Krumholz is supported by grant 1R01 HL081153-03 from the National Heart, Lung, and Blood Institute, and grant 1R01 HS016929-02 from the Agency for Healthcare Research and Quality and the United Health Foundation. We did not receive any additional funding, including pharmaceutical industry funds, for the preparation of this manuscript or any related research.
 Conflict of Interest: All authors report no conflicts of interest.
 Authorship: Catherine Wong was affiliated with Yale University as a Sarnoff Cardiovascular Research Fellow during the time the work was conducted. All authors had access to the data and a role in writing the manuscript.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 2

P. 136-143 - février 2011 Regresar al número
Artículo precedente Artículo precedente
  • Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema
  • Harikrishna Makani, Sripal Bangalore, Jorge Romero, Omar Wever-Pinzon, Franz H. Messerli
| Artículo siguiente Artículo siguiente
  • Smoking Cessation Reduces Postoperative Complications: A Systematic Review and Meta-analysis
  • Edward Mills, Oghenowede Eyawo, Ian Lockhart, Steven Kelly, Ping Wu, Jon O. Ebbert

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.